Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors

The Oncologist(2023)10.1093/oncolo/oyad219Source: DataRank Database

Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors is a research paper published in The Oncologist (2023). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.70)OA: goldTopics (42)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Seungyeon Jung ORCID,Fei Ye ORCID,Lili Sun ORCID,Douglas B. Johnson ORCID,Rajiv Agarwal ORCID

Live enrichment

PubMed:37543031 PMC:PMC10546833 OpenAlex:https://openalex.org/W4385604869

National Institutes of Health

Grant: K12CA090625

National Institutes of Health

Grant: 2K12CA090625-06

Vanderbilt Clinical Oncology Research Career Development Program

National Cancer Institute

FWCI

0.70

Citation Percentile

0.7%

Citation Trend

2024

2025

goldLicense: cc-by

journalhttps://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyad219/51044622/oyad219.pdf

publisherhttps://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyad219/51044622/oyad219.pdf

publisherhttps://academic.oup.com/oncolo/article-pdf/28/10/911/51821338/oyad219.pdf

journalhttps://doi.org/10.1093/oncolo/oyad219

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37543031

Fields of Study

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementMelanoma and MAPK Pathways03 medical and health sciences0302 clinical medicineHumansPrognosisImmune Checkpoint InhibitorsMelanomaTerminal CareNeoplasms, Second PrimaryRisk AssessmentRetrospective Studies

MeSH Terms

Immune Checkpoint InhibitorsHumansMelanomaPrognosisRetrospective StudiesTerminal CareNeoplasms, Second PrimaryRisk Assessment

Keywords

MedicineInternal medicineMelanomaPalliative careOncologyEnd-of-life carePerformance statusCancerCohortIntensive care medicineHospicePrognosticationImmune Checkpoint InhibitionTerminal CareHumansNeoplasms, Second PrimaryMelanoma and Cutaneous MalignanciesPrognosisImmune Checkpoint InhibitorsRisk AssessmentRetrospective Studies